NASDAQ : FENC

Fennec Pharmaceuticals Inc.

$11.575 USD

$0.73 (6.78%)

Volume
224.81K
Average Volume
265.12K
Market Capitalization
$402.08M
P/E Ratio
-37.69
Dividend Yield
0.00%
Price Target
$16.00
Year High
$11.66
Year Low
$5.65
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$6.98
Company Overview

NASDAQ

Jeffrey S. Hackman

Biotechnology

Healthcare

FENC

35

US

USD

https://www.fennecpharma.com

919 636 4530

31447P100

0001211583

Liquidity Metrics

0.00

6.98

6.78

4.19

0.00

Sales & Valuation

$44.64M

7.88

10.55

-69.61

-0.17

Profitability

-$0.36

-$9.74M

-16.42%

-16.22%

-54.75%

-11.66%

P/E Metrics

-37.69

-2.70

-2.70

Analyst Price Target & Rating

$16.00

$16.00

$16.00

Strong Sell

1/5

7 Analysts

-27.66%

Financial Health Scores

3.50

5/9

$57.29M

$71.82M

$34.15M

-$6.78M

Key Metrics (TTM)

$361.9M

7.10

-54.24

6.98

-54.75%

-9.05%

-2.11%

-1.44%

-273 days

Company Executives
Name Title
Pierre S. Sayad Chief Medical Officer
Jeffrey S. Hackman Chief Executive Officer & Director
Lei Fang President of Pharstat Inc
Mark Gowland Controller
Robert C. Andrade Chief Financial Officer
Terry Evans Chief Commercial Officer
Christiana Cioffi Chief Strategy Officer
Poll Results

No votes yet today — be the first to share your view!

About Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Stock

Fennec Pharmaceuticals Inc. operates as a biopharmaceutical firm. Its leading investigational drug in clinical development is PEDMARK, a specialized formulation of sodium thiosulfate. This treatment is designed to shield young cancer patients from hearing damage (ototoxicity) that can be induced by platinum-based chemotherapy. The company, which was founded in 1996, previously operated under the name Adherex Technologies Inc. before officially rebranding as Fennec Pharmaceuticals Inc. in September 2014. Its corporate headquarters are situated in Research Triangle Park, North Carolina. ...

Fennec Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 11, 2026

2026-08-05 07:01:00

RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its second quarter 2026 financial results before the opening of the U.S. financial markets on Tuesday, August 11, 2026. Management will host a conference call and webcast that day to discuss the Company's financial and business results.

Adherex Technologies Inc. (NASDAQ:FENC) Receives Consensus Rating of “Moderate Buy” from Analysts

2026-08-04 02:15:41

Shares of Adherex Technologies Inc. (NASDAQ: FENC - Get Free Report) have received an average recommendation of "Moderate Buy" from the seven analysts that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, four have given a buy recommendation and one

Is the Options Market Predicting a Spike in Adherex Technologies Stock?

2026-07-06 14:26:04

Investors need to pay close attention to FENC stock based on the movements in the options market lately.

Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

2026-06-22 06:00:00

RESEARCH TRIANGLE PARK, N.C., June 22, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced that on June 10, 2026, the Compensation Committee of the Company's Board of Directors approved the grant of incentive stock option awards (“ISOs”) to purchase an aggregate of 15,000 of the Company's common shares to one new non-executive employee of the Company with a grant date of June 22, 2026 under the Company's 2026 Equity Inducement Plan (the “Inducement Plan”). The ISOs were granted as inducements material to the employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

2026-06-15 06:00:00

RESEARCH TRIANGLE PARK, N.C., June 15, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced that on June 10, 2026, the Compensation Committee of the Company's Board of Directors approved the grant of incentive stock option awards (“ISOs”) to purchase an aggregate of 10,000 of the Company's common shares to one new non-executive employee of the Company with a grant date of June 15, 2026 under the Company's 2026 Equity Inducement Plan (the “Inducement Plan”). The ISOs were granted as inducements material to the employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

Fennec Announces Results of Annual Meeting

2026-06-10 16:30:00

RESEARCH TRIANGLE PARK, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy circular dated April 28, 2026 were elected as directors of the Company at the Annual General and Special Meeting of Shareholders held online on June 10, 2025.

Adherex Technologies' PEDMARK Push Targets Larger AYA Market After Record Quarter

2026-05-23 10:06:55

Fennec Pharmaceuticals NASDAQ: FENC executives outlined the company's commercial strategy for PEDMARK, its sodium thiosulfate product used to prevent cisplatin-related hearing loss, during a fireside chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference.

Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting

2026-05-21 18:01:00

~ Growing Independent Research Efforts are Expanding Evidence Base Around How PEDMARK ® (sodium thiosulfate injection) May Benefit Broader and More Diverse Patient Populations ~

Frequently Asked Questions

What is the current Fennec Pharmaceuticals Inc. (FENC) stock price?

Fennec Pharmaceuticals Inc.(NASDAQ:FENC) stock price is $11.575 in the last trading session. During the trading session, FENC stock reached the peak price of $11.66 while $5.65 was the lowest point it dropped to. The percentage change in FENC stock occurred in the recent session was 6.78% while the dollar amount for the price change in FENC stock was $0.73.

FENC's industry and sector of operation?

The NASDAQ listed FENC is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of FENC?

Pierre S. Sayad | Chief Medical Officer
Jeffrey S. Hackman | Chief Executive Officer & Director
Lei Fang | President of Pharstat Inc
Mark Gowland | Controller
Robert C. Andrade | Chief Financial Officer

How many employees does FENC have?

Number of FENC employees currently stands at 35. FENC operates from 68 TW Alexander Drive, Research Triangle Park, NC 27709, US.

Link for FENC official website?

Official Website of FENC is: https://www.fennecpharma.com

How do I contact FENC?

FENC could be contacted at phone #919 636 4530 and can also be accessed through its website. FENC operates from 68 TW Alexander Drive, Research Triangle Park, NC 27709, US.

How many shares of FENC are traded daily?

The average number of FENC shares traded daily for last 3 months was 265.12K.

What is the market cap of FENC currently?

The market value of FENC currently stands at $402.08M with its latest stock price at $11.575